Difference between revisions of "EP Measure Specifications Overview"

Revision as of 21:35, 27 August 2010

 <td class=xl70 width=564 style='border-top:none;border-left:none;width:423pt'>Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside parameters, a follow-up plan is documented.</td>

<tr height=40 style='height:30.0pt'> <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0575</td> <td class=xl73 style='border-top:none;border-left:none'>NCQA</td> <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: HbA1c Control (<8%)</td> <td class=xl70 width=564 style='border-top:none;border-left:none;width:423pt'>The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had HbA1c <8.0%.</td> <td class=xl66 style='border-top:none;border-left:none'> </td> </tr> </table>

Measure		Recommended Measure Title	Recommended Measure Description
Measure	Developer	Title	Description
0001	AMA	Asthma Assessment	Percentage of patients aged 5 through 40 years with a diagnosis of asthma and who have been seen for at least 2 office visits, who were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms.
0002	NCQA	Appropriate Testing for Children with Pharyngitis	The percentage of children 2–18 years of age who were diagnosed with Pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.
0004	NCQA	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	The percentage of adolescent and adult patients with a new episode of alcohol and other drug (AOD) dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis and who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.
0012	AMA	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	Percentage of patients, regardless of age, who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal visit.
0013	AMA	Hypertension: Blood Pressure Measurement	Percentage of patient visits for patients aged 18 years and older with a diagnosis of hypertension who have been seen for at least 2 office visits, with blood pressure (BP) recorded.
0014	AMA	Prenatal Care: Anti-D Immune Globulin	Percentage of D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation.
0018	NCQA	Controlling High Blood Pressure	The percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose BP was adequately controlled during the measurement year.
0024	NCQA	Weight Assessment and Counseling for Children and Adolescents	The percentage of patients 2-17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the measurement year.
0027	NCQA	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	The percentage of patients 18 years of age and older who were current smokers or tobacco users, who were seen by a practitioner during the measurement year and who received advice to quit smoking or tobacco use or whose practitioner recommended or discussed smoking or tobacco use cessation medications, methods or strategies.
0028a	AMA	Preventive Care and Screening Measure Pair: a.Tobacco Use Assessment	Percentage of patients aged 18 years or older who have been seen for at least 2 office visits, who were queried about tobacco use one or more times within 24 months.
0028b	AMA	Preventive Care and Screening Measure Pair: b.Tobacco Cessation Intervention	Percentage of patients aged 18 years and older identified as tobacco users within the past 24 months who received cessation intervention.
0031	NCQA	Breast Cancer Screening	The percentage of women 40–69 years of age who had a mammogram to screen for breast cancer.
0032	NCQA	Cervical Cancer Screening	The percentage of women 21-64 years of age who received one or more Pap tests to screen for cervical cancer.
0033	NCQA	Chlamydia Screening for Women	The percentage of women 15-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.
0034	NCQA	Colorectal Cancer Screening	The percentage of adults 50–75 years of age who had appropriate screening for colorectal cancer.
0036	NCQA	Use of Appropriate Medications for Asthma	The percentage of patients 5-50 years of age during the measurement year who were identified as having persistent asthma and were appropriately prescribed medication during the measurement year. Report three age stratifications (5-11 years, 12-50 years, and total).
0038	NCQA	Childhood immunization Status	The percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); two H influenza type B (HiB); three hepatitis B (Hep B), one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and two separate combination rates.
0041	AMA	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	Percentage of patients aged 50 years and older who received an influenza immunization during the flu season (September through February).
0043	NCQA	Pneumonia Vaccination Status for Older Adults	The percentage of patients 65 years of age and older as of January 1 of the measurement year who have ever received a pneumococcal vaccine.
0047	AMA	Asthma Pharmacologic Therapy	Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment.
0052	NCQA	Low Back Pain: Use of Imaging Studies	The percentage of patients with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of diagnosis.
0055	NCQA	Diabetes: Eye Exam	The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by an eye care professional .
0056	NCQA	Diabetes: Foot Exam	The percentage of patients aged 18-75 years with diabetes (type 1 or type 2) who had a foot exam (visual inspection, sensory exam with monofilament, or pulse exam).
0059	NCQA	Diabetes: HbA1c Poor Control	The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had HbA1c >9.0%.
0061	NCQA	Diabetes: Blood Pressure Management	The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had BP <140/90 mmHg.
0062	NCQA	Diabetes: Urine Screening	The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had a nephropathy screening test or evidence of nephropathy .
0064	NCQA	Diabetes: LDL Management & Control	The percentage of patients 18–75 years of age with diabetes (type 1 or type 2) who had LDL-C <100mg/dL.
0067	AMA	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy.
0068	NCQA	Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic	The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had documentation of use of aspirin or another antithrombotic during the measurement year.
0070	AMA	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)	Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy.
0073	NCQA	Ischemic Vascular Disease (IVD): Blood Pressure Management	The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and whose most recent blood pressure is in control (<140/90 mmHg).
0074	AMA	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol	Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines).
0075	NCQA	Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control	The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had a complete lipid profile performed during the measurement year and whose LDL-C was <100 mg/dL.
0081	AMA	Heart Failure (HF) : Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Percentage of patients aged 18 years and older with a diagnosis of heart failure and LVSD (LVEF < 40%) who were prescribed ACE inhibitor or ARB therapy.
0083	AMA	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were prescribed beta-blocker therapy.
0084	AMA	Heart Failure (HF) : Warfarin Therapy Patients with Atrial Fibrillation	Percentage of all patients aged 18 and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy.
0086	AMA	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least 2 office visits, who have an optic nerve head evaluation during one or more office visits within 12 months.
0088	AMA	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.
0089	AMA	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the on-going care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.
0105	NCQA	Anti‐depressant medication management: (a) Effective Acute Phase Treatment, (b)Effective Continuation Phase Treatment	The percentage of patients 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication treatment.
0385	AMA	Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.
0387	AMA	Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.
0389	AMA	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer
0421	QIP	Adult Weight Screening and Follow-Up </span>

Difference between revisions of "EP Measure Specifications Overview"

Revision as of 21:35, 27 August 2010

Navigation menu

Views

Personal tools

Navigation

Search

Tools

@@ Line 20: / Line 20: @@
   </tr>
   <tr height=60 style='height:45.0pt'>
-   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>0002</td>
+   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0002|0002]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Appropriate Testing for Children with Pharyngitis</td>
@@ Line 26: / Line 26: @@
   </tr>
   <tr class=xl71 height=100 style='height:75.0pt'>
-   <td height=100 class=xl72 style='height:75.0pt;border-top:none'>0004</td>
+   <td height=100 class=xl72 style='height:75.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0004|0004]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement</td>
@@ Line 32: / Line 32: @@
   </tr>
   <tr class=xl71 height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0012</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0012|0012]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)</td>
@@ Line 38: / Line 38: @@
   </tr>
   <tr class=xl71 height=60 style='height:45.0pt'>
-   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>0013</td>
+   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0013|0013]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Hypertension: Blood Pressure Measurement</td>
@@ Line 44: / Line 44: @@
   </tr>
   <tr height=60 style='height:45.0pt'>
-   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>0014</td>
+   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0014|0014]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Prenatal Care: Anti-D Immune Globulin</td>
@@ Line 50: / Line 50: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0018</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0018|0018]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Controlling High Blood Pressure</td>
@@ Line 56: / Line 56: @@
   </tr>
   <tr height=60 style='height:45.0pt'>
-   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>0024</td>
+   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0024|0024]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Weight Assessment and Counseling for Children and Adolescents</td>
@@ Line 62: / Line 62: @@
   </tr>
   <tr class=xl71 height=100 style='height:75.0pt'>
-   <td height=100 class=xl72 style='height:75.0pt;border-top:none'>0027</td>
+   <td height=100 class=xl72 style='height:75.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0027|0027]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl67 width=335 style='border-top:none;border-left:none;width:251pt'>Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies</td>
@@ Line 68: / Line 68: @@
   </tr>
   <tr class=xl71 height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0028a</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0028a|0028a]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Preventive Care and Screening Measure Pair: a.Tobacco Use Assessment</td>
@@ Line 74: / Line 74: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0028b</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0028b|0028b]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Preventive Care and Screening Measure Pair: b.Tobacco Cessation Intervention</td>
@@ Line 80: / Line 80: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0031</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0031|0031]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Breast Cancer Screening</td>
@@ Line 86: / Line 86: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0032</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0032|0032]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Cervical Cancer Screening</td>
@@ Line 92: / Line 92: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0033</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0033|0033]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Chlamydia Screening for Women</td>
@@ Line 98: / Line 98: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0034</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0034|0034]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Colorectal Cancer Screening</td>
@@ Line 104: / Line 104: @@
   </tr>
   <tr height=80 style='height:60.0pt'>
-   <td height=80 class=xl72 style='height:60.0pt;border-top:none'>0036</td>
+   <td height=80 class=xl72 style='height:60.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0036|0036]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Use of Appropriate Medications for Asthma</td>
@@ Line 110: / Line 110: @@
   </tr>
   <tr class=xl71 height=120 style='height:90.0pt'>
-   <td height=120 class=xl72 style='height:90.0pt;border-top:none'>0038</td>
+   <td height=120 class=xl72 style='height:90.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0038|0038]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Childhood immunization Status</td>
@@ Line 116: / Line 116: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0041</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0041|0041]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Preventive Care and Screening: Influenza Immunization for Patients &#8805; 50 Years Old</td>
@@ Line 122: / Line 122: @@
   </tr>
   <tr class=xl71 height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0043</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0043|0043]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Pneumonia Vaccination Status for Older Adults</td>
@@ Line 128: / Line 128: @@
   </tr>
   <tr height=60 style='height:45.0pt'>
-   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>0047</td>
+   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0047|0047]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Asthma Pharmacologic Therapy</td>
@@ Line 134: / Line 134: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0052</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0052|0052]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Low Back Pain: Use of Imaging Studies</td>
@@ Line 140: / Line 140: @@
   </tr>
   <tr height=60 style='height:45.0pt'>
-   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>0055</td>
+   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0055|0055]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: Eye Exam</td>
@@ Line 146: / Line 146: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0056</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0056|0056]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: Foot Exam</td>
@@ Line 152: / Line 152: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0059</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0059|0059]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: HbA1c Poor Control</td>
@@ Line 158: / Line 158: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0061</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0061|0061]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl67 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: Blood Pressure Management</td>
@@ Line 164: / Line 164: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0062</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0062|0062]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: Urine Screening</td>
@@ Line 170: / Line 170: @@
   </tr>
   <tr class=xl71 height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0064</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0064|0064]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: LDL Management &amp; Control</td>
@@ Line 176: / Line 176: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0067</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0067|0067]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD</td>
@@ Line 182: / Line 182: @@
   </tr>
   <tr class=xl71 height=140 style='height:105.0pt'>
-   <td height=140 class=xl72 style='height:105.0pt;border-top:none'>0068</td>
+   <td height=140 class=xl72 style='height:105.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0068|0068]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl67 width=335 style='border-top:none;border-left:none;width:251pt'>Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic</td>
@@ Line 188: / Line 188: @@
   </tr>
   <tr height=60 style='height:45.0pt'>
-   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>0070</td>
+   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0070|0070]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)</td>
@@ Line 194: / Line 194: @@
   </tr>
   <tr class=xl71 height=120 style='height:90.0pt'>
-   <td height=120 class=xl72 style='height:90.0pt;border-top:none'>0073</td>
+   <td height=120 class=xl72 style='height:90.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0073|0073]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Ischemic Vascular Disease (IVD): Blood Pressure Management</td>
@@ Line 200: / Line 200: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0074</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0074|0074]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol</td>
@@ Line 206: / Line 206: @@
   </tr>
   <tr class=xl71 height=140 style='height:105.0pt'>
-   <td height=140 class=xl72 style='height:105.0pt;border-top:none'>0075</td>
+   <td height=140 class=xl72 style='height:105.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0075|0075]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control</td>
@@ Line 212: / Line 212: @@
   </tr>
   <tr class=xl71 height=80 style='height:60.0pt'>
-   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>0081</td>
+   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0081|0081]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl74 width=335 style='border-top:none;border-left:none;width:251pt'>Heart Failure (HF) : Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)</td>
@@ Line 218: / Line 218: @@
   </tr>
   <tr class=xl71 height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0083</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0083|0083]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl74 width=335 style='border-top:none;border-left:none;width:251pt'>Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)</td>
@@ Line 224: / Line 224: @@
   </tr>
   <tr class=xl71 height=40 style='height:30.0pt'>
-   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>0084</td>
+   <td height=40 class=xl68 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0084|0084]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl74 width=335 style='border-top:none;border-left:none;width:251pt'>Heart Failure (HF) : Warfarin Therapy Patients with Atrial Fibrillation</td>
@@ Line 230: / Line 230: @@
   </tr>
   <tr class=xl71 height=60 style='height:45.0pt'>
-   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>0086</td>
+   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0086|0086]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl74 width=335 style='border-top:none;border-left:none;width:251pt'>Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation</td>
@@ Line 236: / Line 236: @@
   </tr>
   <tr class=xl71 height=80 style='height:60.0pt'>
-   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>0088</td>
+   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0088|0088]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl74 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy</td>
@@ Line 242: / Line 242: @@
   </tr>
   <tr class=xl71 height=100 style='height:75.0pt'>
-   <td height=100 class=xl68 style='height:75.0pt;border-top:none'>0089</td>
+   <td height=100 class=xl68 style='height:75.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0089|0089]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl74 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care</td>
@@ Line 248: / Line 248: @@
   </tr>
   <tr class=xl71 height=60 style='height:45.0pt'>
-   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>0105</td>
+   <td height=60 class=xl72 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0105|0105]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Anti&#8208;depressant medication management: (a) Effective Acute Phase Treatment, (b)Effective Continuation Phase Treatment</td>
@@ Line 254: / Line 254: @@
   </tr>
   <tr class=xl71 height=80 style='height:60.0pt'>
-   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>0385</td>
+   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0385|0385]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Oncology Colon Cancer:   Chemotherapy for Stage
@@ Line 261: / Line 261: @@
   </tr>
   <tr class=xl71 height=60 style='height:45.0pt'>
-   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>0387</td>
+   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0387|0387]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Oncology Breast Cancer:   Hormonal Therapy for
@@ Line 269: / Line 269: @@
   </tr>
   <tr height=80 style='height:60.0pt'>
-   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>0389</td>
+   <td height=80 class=xl68 style='height:60.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0389|0389]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>AMA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Prostate Cancer:   Avoidance of Overuse of Bone
@@ Line 276: / Line 276: @@
   </tr>
   <tr height=60 style='height:45.0pt'>
-   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>0421</td>
+   <td height=60 class=xl68 style='height:45.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0421|0421]]</td>
    <td class=xl69 style='border-top:none;border-left:none'>QIP</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Adult Weight Screening and Follow-Up  </span></td>
@@ Line 282: / Line 282: @@
   </tr>
   <tr height=40 style='height:30.0pt'>
-   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>0575</td>
+   <td height=40 class=xl72 style='height:30.0pt;border-top:none'>[[EP_Measure_Specifications_Index#NQF_0575|0575]]</td>
    <td class=xl73 style='border-top:none;border-left:none'>NCQA</td>
    <td class=xl70 width=335 style='border-top:none;border-left:none;width:251pt'>Diabetes: HbA1c Control (&lt;8%)</td>